Median Effective Dose of Dexmedetomidine in Elective Upper Limb Lidocaine Intravenous Regional Anesthesia

PHASE4CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

February 29, 2020

Study Completion Date

March 1, 2020

Conditions
Intravenous Drug Usage
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia

Trial Locations (1)

Unknown

South Valley University, Qina

All Listed Sponsors
collaborator

Tanta University

OTHER

lead

South Valley University

OTHER

NCT04304157 - Median Effective Dose of Dexmedetomidine in Elective Upper Limb Lidocaine Intravenous Regional Anesthesia | Biotech Hunter | Biotech Hunter